Global Diagnostic Testing Markets

Venue: The Hatton

Location: London, United Kingdom

Event Date/Time: Jun 25, 2003 End Date/Time: Jun 26, 2003
Registration Date: Jun 26, 2003
Report as Spam

Description

“The panel of speakers is of exceptional quality and all the issues facing the diagnostics industry today have been included which should make this an unmissable event to attend”
Doris-Ann Williams, Director General, British In Vitro Diagnostics Association

Discover the latest industry developments at SMi’s…
Opportunities & Technology Trends in
Global Diagnostic
Testing Markets
25th & 26th June 2003, The Hatton, London



A unique opportunity to learn from leading industry experts including:

 Heino Von Prondzynski, Member, Executive Committee & Head, Diagnostics, F Hoffman-La Roche
 Dr William Wallen, Senior Vice President, Research, Bayer Diagnostics
 Richard Gutowski, European & Compliance Section Head, Department of Health, Medical Devices Agency
 Edward Michael, Corporate Vice President & General Manager, Abbott
 George Zajicek, Business Development Director, Axis-Shield
 Anne Bailey, Vice President, Diagnostics, Nuvelo (formally Variagenics)
 Dr Bernd Haase, Senior Business Development Manager, Europe, Affymetrix
 Dr Jean-Michel Cosséry, Executive Vice President, Product Strategy, Amersham Health


Benefits of Attending

 BUSINESS STRATEGIES: explore the opportunities that arise from collaborations, strategic alliances and
outsourcing
 REGULATIONS: find out how recent regulation changes will affect your company
 POINT OF CARE TESTING: review the current markets and learn how they will grow
 GLUCOSE MONITORING: gain an insight into how the glucose testing markets will develop
 HEART DISEASE: discover how the key technologies are performing and where the new opportunities lie
 MOLECULAR DIAGNOSTICS: learn how this promising industry will shape up
 CANCER DIAGNOSTICS: examine the current global landscape, discover where future market potential lies
 PERSONALISED MEDICINE: discover the strategic advantages and points of impact




PLUS A HALF DAY EXECUTIVE BRIEFING
Innovation in the Product Development Cycle
27th June 2003
The Hatton, London
In association with: Nova Biomedical & HLB

Day One – 25th June 2003

8.30 Registration & Coffee

9.00 Chairperson's Opening Remarks
Doris-Ann Williams, Director General, British In Vitro Diagnostics Association

KEYNOTE ADDRESS
9.10 An overview of the current state of the global diagnostics industry
 Global trends and counter trends
 Market segments - home diagnostics, point of care, molecular diagnostics and cancer diagnostics
 Opportunities and threats to the industry
 Sources of market data
 Strategic planning in diagnostics
Andy Anderson, Managing Director, Crawford Medical

INDUSTRY CONSOLIDATION
9.40 Why super-companies exist and how they got there
 Driving factors for consolidation
 How will it affect the IVD industry?
 Advantages and disadvantages of the consolidation trend
 What does it mean for Bayer Diagnostics?
 Impact on the future of diagnostics
Dr William Wallen, Senior Vice President, Research, Bayer Diagnostics

CASE STUDY : ROCHE
10.20 Mergers and acquisitions
 What the big players are looking for
 How to select suitable partners
 How a merger will benefit you
 Potential problems that may occur
 Why fragmentation still exists
Heino Von Prondzynski, Member, Executive Committee & Head, Diagnostics, F Hoffman-La Roche

11.00 Morning Coffee

CASE STUDY: LIFESCAN
11.20 How glucose monitoring is transforming the lives of diabetics
 Brief outline of the technology
 The various roles of glucose monitoring in managing diabetes
 The growth of the markets
 The industry prospects
 Future markets
Dr David Horwitz, Vice President, Medical & Clinical Affairs, LifeScan

12.00 OUTSOURCING AS A STRATEGY
Thinking out of the box
 Learn how to enhance your product development cycle
 How will outsourcing enhance your company?
 Gain an insight into the strategy for outsourcing
 What are the benefits of outsourcing?
 Learn about the problems you may encounter and how to avoid them
Jeffrey DuBois, Vice President, Business Development, Nova Biomedical

12.40 Networking Lunch

KEY TECHNOLOGY DRIVES
2.00 Critical technology trends in the diagnostics industry
 Key technology sectors
 The technologies that are big
 The technologies that are going to be big
 Predicted growth
Edward Michael, Corporate Vice President & General Manager, Abbott

POINT OF CARE TESTING
2.40 Decentralisation of patient testing
 The technologies involved
 Market analysis: the leading suppliers
 Cost pressures and perceived barriers
 Moderators of growth
 Importance and benefits of in office testing
 Attitudes of critical care nurses, physicians and doctors
Clint Severson, President, Chief Executive Officer & Chairman, Abaxis

3.20 Afternoon Tea

HEART DISEASE DIAGNOSTICS
3.40 Commercial opportunities in heart disease IVDs
 What are the specific areas of cardiovascular diagnosis?
 Learn what products are on the market and how they are performing
 Gain an understanding of the current market size and how it is set to grow
 What are the hot topics of research and when will they emerge from R&D?
 Where do future opportunities lie?
George Zajicek, Business Development Director, Axis-Shield Diagnostics

4.20 A1C: THE GLUCOSE OF TOMORROW?
 Diabetes disease management - glucose and A1c in partnership
 The technologies and marketing strategies employed in today’s A1c testing market
 The A1c Point of Care market inside and outside of the USA
 The historic parallels between glucose and A1c
 The future of A1c testing
John Curtis, Managing Director, Provalis Diagnostics

5.00 Chairperson’s Closing Remarks and Close of Day One


Day Two - 26th June 2003

8.30 Re-registration & Coffee

9.00 Chairman's Opening Remarks
Andy Anderson, Managing Director, Crawford Medical

MOLECULAR DIAGNOSTICS
9.10 How will this promising industry shape up?
 Identification of the current technology trends
 A global assessment through an exploration of the current landscape
 Review of the technology platforms including immunoassays, probe-based nucleic acid assays, microarrays and sequencing
 Identify feasible market opportunities through the identification of expanding markets
Anne Bailey, Vice President, Diagnostics, Nuvelo (formally Variagenics)

ONCOLOGY AND MOLECULAR DIAGNOSTICS
9.40 Commercialization strategies
 Intellectual property in diagnostics
 Technology Licensing vs product development
 Commercialization/ partnering strategies
 Molecular diagnostics and oncology- the opportunity
 Outline of EXACT’s technologies and their applications
 EXACT’s commercial plan
Jeffrey Walsh, Vice President, Business Development & Strategy, EXACT Sciences

MICROARRAYS ARE APPROACHING DIAGNOSTIC APPLICATIONS
10.20 High density DNA microarrays on their cross-tie from R&D to diagnostic use
 Review of the microarray industry and its market segmentation
 The importance of technological developments for high-throughput analysis
 Breakthrough applications in RNA expression analysis
 Novel high density microarray assays for genotyping
 Why are collaborations essential to accelerate growth?
 Market opportunities for diagnostic microarrays
Dr Bernd Haase, Senior Business Development Manager, Europe, Affymetrix

11.0 Morning Coffee

THE DIAGNOSTIC IMAGING COMPANY
11.20 An opportunity or threat to the pharmaceutical industry?
 What are the positive and negative aspects of aligning diagnostic and therapeutic companies?
 With targeted medicine will the pharmaceutical industry lose or gain market share?
 The role in vivo molecular imaging will play in personalised medicine
 Which technologies will be used - are these in vivo technologies a barrier to entry?
 In vivo diagnostic imaging - threat or opportunity to the pharmaceutical industry?
 How diagnostic pharmaceutical and therapeutic pharmaceutical companies can work together for mutual benefit to achieve the personalised medicine goal
Dr Jean-Michel Cosséry, Executive Vice President, Product Strategy, Amersham Health



DIAGNOSTICS… AS PART OF THE CURE
12.00 Innovative methods for early cancer diagnostics
 The rapid emergence of in vitro cancer diagnostics
 Our technologies and approach to market
 ImmunoCyt/uCyt+ - bladder cancer diagnostics
 uPM3 - prostate cancer diagnostics
 LCM10 - lung cancer diagnostics
 Business strategy, highlights and objectives
Piere Désy, President & Chief Executive Officer, DiagnoCure

12.40 Networking Lunch

REGULATIONS: A US PERSPECTIVE
2.00 FDA initiatives and their impact on your business
 Introduction to the new IVD office
 Review of the current issues in the US market
 The new initiatives you should be aware of
 How new initiatives will affect your company
 Reimbursement issues
Thomas Soriano, President & Chief Executive Officer, Diagnostic Oncology CRO

REIMBURSEMENT PRACTICES IN THE EU
2.40 An insight into reimbursement issues
 First understand local disease management
 Identify the payers and budget holders
 Appreciate the significance of formal listings
 Understand the role of other guidance
 Prepare to meet all the requirements
 Use Health Technology Assessment to your advantage
Paula Wittels, Director, Operations, Quintiles Consulting

3.20 Afternoon Tea

FUTURE DEVELOPMENTS
3.40 Theranostics - transforming the art of disease management
 An outline of the concept
 Features and benefits of theranostics
 Market opportunities and growth potential
 Current strategies
Sander Tufte, Director, Theranostics, Axis-Shield

4.20 REGULATIONS: A EUROPEAN PERSPECTIVE
 Review of current European regulatory issues
 The new IVD directive 98/79/EC
Richard Gutowski, European & Compliance Section Head, Department of Health, Medical Devices Agency

5.00 Chairman's Closing Remarks and Close of Conference



Half Day Executive Briefing

Innovation in the Product Development Cycle
27th June 2003
The Hatton, London
In association with: Nova Biomedical & HLB

About the Briefing
This Briefing will provide insight into innovative product development cycles. You will learn how to integrate all aspects of product development, from the initial assessment of market opportunities, through product concept and design, to final manufacture and launch

Briefing Timetable

8.30 Registration & Coffee

9.00 Recognition of corporate cultures in homogeneous organisations
OEM market dynamics
Needs/issues
Trends
Process for success
Experience/skills required
Opportunity assessment / competitive environment (barriers to entry)
Field research / market requirements
Product definition (early market specification)
Product / device design / product specification (functional)
Product / device proof of concept (breadboard)
Product development:
Mechanical/electrical/software design / prototype (Alpha)
Market confirmation
Proprietary process development
Manufacturing equipment design & build
Manufacture
Pilot production (Beta)
Testing & certification
Production (ramp up)
Field support / depot repair

10.30 Morning Coffee

10.50 CASE STUDY
Independent autonomous integration (critical success factors)
a la carte cases
Outsourcing as a strategy
Site visit requirements
Validation
Benefits of outsourcing
Strategy for innovation
Change status quo / challenge NIH
Mind the gap in critical human resources
Time / cost / deliverable benefits
Conclusion

12.30 Close of Briefing

About your Briefing Leaders

Jeffrey DuBois
Jeffrey DuBois is Vice President of Business Development at Nova Biomedical and has worked there for four years. Prior to Nova Biomedical, Dr DuBois was the Executive Director for Laboratory Services at University Hospital Health System, Cleveland, OH and on the faculty of the Case Western Reserve University School of Medicine. He served as the Chair of the NCCLS POC Connectivity Standard Committee and is currently serving as the Chair for the NCCLS Area Committee for POC Testing.
He currently holds 2 patents and has been published over 50 times. Dr DuBois received his PhD from St. Bonaventure University and M.B.A from Northwestern University



Walter Herbst
Walter Herbst founded HLB over 40 years ago. He holds over 85 patents and currently serves as Chairman of the firm. Mr Herbst's academic life includes being Director of the Master Product Development Program of Northwestern University. He also teaches at the McCormick School of Applied Science and Engineering, as well as Northwestern University's Kellogg Graduate School of Management.



About Nova Biomedical
Since its formation in 1976 Nova Biomedical has been the world's leading innovator in the development of Ion Selective Electrode (ISE) and biosensor technology for medical diagnostics. Their Technology Partnership (TP) unites them with HLB and Foster-Miller, and offers expertise in every step of the product development process from market research and product design to proprietary process development and manufacturing as a single contracting entity.

Together they produced the most advanced device in the blood glucose monitoring field, taking it from concept to market in only 18 months.

Venue

The Hatton
51-53 Hatton Gardens
London
United Kingdom
MORE INFO ON THIS VENUE